After a break with Philidor, outlook from Valeant is more guarded

Embattled Valeant Pharmaceuticals is slashing its expectations for the current quarter and 2015 as a whole and issuing a guarded outlook for next year as well.

See Full Article

Valeant is lowering its per-share profit expectations for the year, reported in U.S. currency, from between $11.67 and $11.87, to between $10.23 and $10.33. That's well short of the analyst estimates.

The drugmaker's outlook for the fourth quarter ending Dec. 31 has been lowered to between $2.55 and $2.65 a share. Analysts expected $3.47 per share and the company's previous estimate was between $4.00 and $4.20 per share.

Valeant's press release didn't specify the reason for the reduced expectations -- which come as the Quebec-based company faces investor dissatisfaction over its handling of a controversy over its pricing and distribution practices, which are being investigated by U.S. authorities.

Chief executive Michael Pearson and other Valeant executives will face questions from analysts at a company briefing this morning.

In October, the Quebec-based company severed ties with a U.S. mail-order pharmacy that distributed specialty drugs for Valeant. It also announced on Tuesday that it will deliver up to US$600 million in annual savings to the U.S. health-care system starting next year after agreeing to cut prices as part of distribution agreements with the large Walgreens retail chain.

Valeant says it will drop wholesale prices for branded prescription-based skin and eye-care products by 10 per cent. Walgreens will also distribute more than 30 of Valeant's branded products at comparable generic prices, starting in the second half of 2016. The average price decrease is expected to be more than 50 per cent, and range between five and 95 per cent.

The company's shares are already down more than 20 per cent for the year, closing Tuesday at C$149.75 on the Toronto Stock Exchange.

Valeant's price cuts don't apply in Canada where the Laval-based company doesn't have similar distribution agreements with pharmacy retailers such as Shopper's Drug Mart, Jean Coutu or the Rexall Group.

The new distribution agreement with Walgreens -- a chain with more than 8,000 retail outlets -- follows Valeant's decision in October to sever ties with mail-order pharmacy Philidor Rx Services. That relationship came to light as a result of a court battle between Valeant and another mail-order pharmacy.

Valeant has been accused of using Philidor to create a network of "phantom pharmacies" to steer pharmacy benefit managers toward Valeant's more expensive drugs, rather than cheaper alternatives.

With files from The Associated Press and the Canadian Press.



Advertisements

Latest Economic News

  • Disability in demand: People with autism offer employers a broader talent pool

    Economic CBC News
    He's a former job pariah who's suddenly a hot new hire, a university graduate with astonishing analytical abilities who could barely answer a question during job interviews. Now the very reason Shawn Bolshin couldn't get a job is the very reason he has one. Source
  • Liberals turn to pasta to move past 3 months of fuss and fury over tax fairness

    Economic CBC News
    When the prepared statements were finished and the floor was opened for questions, the first reporter in line wanted to question Bill Morneau, about not just the government's tax changes, but also whether the finance minister's personal wealth was being ethically managed. Source
  • Asian stocks little changed after Wall Street hits new highs

    Economic CTV News
    BEIJING - Asian stocks were little-changed Tuesday after Wall Street's major indexes rose to new highs as China prepared to open a key political meeting. KEEPING SCORE: The Shanghai Composite Index was off 0.1 per cent at 3,374.66 while Tokyo's Nikkei 225 was unchanged at 21,260.89. Source
  • Bombardier to partner with Airbus on CSeries program

    Economic CBC News
    Fred Cromer, president of commercial aircraft at Bombardier Aerospace, speaks to reporters at Bombardier's plant in Mirabel, Que. Source
  • Europe's Airbus to buy majority stake in Bombardier CSeries program

    Economic CBC News
    Fred Cromer, president of commercial aircraft at Bombardier Aerospace, speaks to reporters at Bombardier's plant in Mirabel, Que. Source
  • Netflix sinking deeper into debt to fuel subscriber growth

    Economic CTV News
    SAN FRANCISCO -- Netflix is sinking deeper into debt in its relentless pursuit of more viewers, leaving the company little margin for error as it tries to build the world's biggest video subscription service. The big burden that Netflix is shouldering hasn't been a major concern on Wall Street so far, as CEO Reed Hastings' strategy has been paying off. Source
  • Airbus to buy majority stake in Bombardier CSeries program

    Economic CTV News
    MONTREAL -- European aircraft giant Airbus Group is buying a majority stake in Bombardier's CSeries program. The two aircraft manufacturers announced the partnership Monday evening, weeks after the United States announced 300 per cent preliminary duties on exports of the aircraft following a complaint from Airbus rival Boeing. Source
  • Airbus shakes up industry with majority stake in Bombardier CSeries program

    Economic CTV News
    MONTREAL -- European aircraft giant Airbus Group is shaking up the global airline business by buying a majority stake in Bombardier's CSeries program and assembling the plane in the U.S. to avoid import duties. The two aircraft manufacturers announced the partnership Monday evening, weeks after the United States announced 300 per cent preliminary duties on exports of the aircraft following a complaint from Airbus rival Boeing. Source
  • Securities regulator sets out rules for Canadian marijuana stocks with U.S. interests

    Economic CBC News
    The Canadian Securities Administrators set out "specific disclosure expectations" for marijuana industry firms with investments in the U.S., offering much-anticipated clarity for companies that operate on both sides of the border. The umbrella organization for Canada's provincial and territorial securities regulators put out a staff notice, saying that cannabis companies must tell investors about certain risks when they invest south of the border — where growing and selling marijuana remains…
  • Regulators set rules for cross-border pot listings

    Economic CTV News
    TORONTO -- The Canadian Securities Administrators set out "specific disclosure expectations" for marijuana industry firms with investments in the U.S., offering much-anticipated clarity for companies that operate on both sides of the border. The umbrella organization for Canada's provincial and territorial securities regulators put out a staff notice, saying that cannabis companies must tell investors about certain risks when they invest south of the border -- where growing and selling…